Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Emyria selected for limited speaking spot at US FDA hearing

13 September 2026 · By · Wire by Fusion42

Published

13 September 2026

Topic

regulatory

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at theaustralian.com.au →

◆ Verified

Fusion42 · 14 September 2026 · Fusion42 review

Emyria has been selected to deliver in-person remarks at a US FDA public hearing on the future therapeutic use of psychedelic drugs, covering provider training, patient safety, access, and clinical data standardisation. The company aims to leverage its experience from Australia to explore opportunities in the US healthcare market.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You can use Emyria's FDA speaking slot to access US markets earlier than competitors without local experience. This hearing is a door to build credibility and partnerships in psychedelic medicine with regulator attention.

◆ Coverage

1 source · 13 Sep 2026

◆ Related on Wire

◆ Topics

HealthFDApsychedelic-therapeuticsregulatory-hearingmental-healthUS-healthcare